EFFECTS OF RALTEGRAVIR ON VIRAL LOADS OF CATS NATURALLY INFECTED BY THE FELINE LEUKEMIA VIRUS.
antiretroviral; infectious diseases; progressive infection; polymerase chain reaction
Feline leukemia virus (FeLV) infection remains highly prevalente in feline practice, and when progressive it presentes severe clinical manifestations, in the vast majority of cases, result in the death of patients. To date, no treatments have been conclusively proven effective against FeLV, they are only symptomatic. Following in vitro studies and some in vivoreports, raltegravir, an antiretroviral integrase inhibitor, appears promising for treating the infection due to the high degree of conservation of active integrase sites present in many retroviruses. The purpose of this study was to enable an effective and safe treatment against FeLV, assesing its efficacy in suppressing virus replication through the analysis of the count of proviral DNA copies and sufficient viral RNA to convert patients with progressive infection into regressive. Patients with progressive infection were randomly divided by drawing lots into a control group and a treated group. The treated group received raltegravir at a dose of 40mg every 12 hours, while the control group received a placebo capsule. Both groups were monitored for clinical progression and laboratory tests, blood samples were collected for Quantitative Polymerase Chain Reaction (qPCR), Real-Time Reverse Transcription (RT-qPCR), complete blood count with platelet count, urea, creatinine, alanine aminotransferase, alkaline phosphatase, total proteins, albumin and globulin, every 5 weeks, for a total of 10 weeks. The data obtained from the present study are subjected to statistical analysis.